Anti il12p40 c17

Manufactured by BioXCell

Anti-IL12p40 C17.8 is a monoclonal antibody that binds to the p40 subunit of interleukin-12 (IL-12). It is designed for use in research applications.

Automatically generated - may contain errors

Lab products found in correlation

Anti ifn γ xmg1, by BioXCell (1 mentions) Anti ifn γ, by BioXCell (1 mentions) Cd3 cd28 dynabead, by Thermo Fisher Scientific (1 mentions) Interleukin 4 (il 4), by R&D Systems (1 mentions) Interleukin 2 (il 2), by R&D Systems (1 mentions) Anti nk1.1 pk136, by BioXCell (1 mentions) Tamoxifen, by Merck Group (1 mentions)

2 protocols using anti il12p40 c17

Adoptive Transfer of Naive and Th2 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Naive CD4⁺ T cells were sorted from spleens as CD4⁺TCRβ⁺CD44^–CD25^–Il4^gfp–PI⁻(Il4^gfp reporter) or CD4⁺TCRβ⁺CD44^–CD25^–Il4^gfp-Ifng^yfp–Il17a^FP635–PI⁻(triple reporter). Th2 cells were cultured for 2 weeks from splenic CD4⁺ cells in vitro with 10 ng/mL IL-4 (R&D), 5 ng/mL IL-2 (R&D), 10 μg/mL anti-IFNγ (XMG1.2, BioXcell), and Mouse T-Activator CD3/CD28 Dynabeads (Life Technologies) in IMDM with 10% FCS. Th2 cells were sorted as CD4⁺TCRβ⁺Il4^gfp+PI⁻(Il4^gfp reporter) or CD4⁺TCRβ⁺Il4^gfp+Ifng^yfp–Il17a^FP635–PI⁻(triple reporter). For each experiment, 0.2x10⁶ to 1x10⁶ cells were adoptively transferred i.v. into recipient C57BL/6 Rag1^–/- mice. Blocking antibodies diluted in PBS (anti-IFNγ, XMG1.2, anti-IL12p40 C17.8, BioXcell) were used at 0.4 or 0.5 mg/ dose.

Coomes S.M., Pelly V.S., Kannan Y., Okoye I.S., Czieso S., Entwistle L.J., Perez-Lloret J., Nikolov N., Potocnik A.J., Biró J., Langhorne J, & Wilson M.S. (2015). IFNγ and IL-12 Restrict Th2 Responses during Helminth/Plasmodium Co-Infection and Promote IFNγ from Th2 Cells. PLoS Pathogens, 11(7), e1004994.

+ Open protocol

+ Expand

Experimental Manipulation of Immune Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

To deplete NK cells, B6 mice were treated i.p. with 200 μg of anti-NK1.1 (PK136, Bio X Cell) 1 d before infection (d −1), on the day of infection (d 0) and every other day after infection for a maximum of 3 wk. To deplete CD8+ or CD4+ T cells, mice were treated i.p. with 200 μg of anti-CD8 T (2.43, Bio X Cell) or anti-CD4 T (GK1.5, Bio X Cell), respectively on d −1 and 0. To neutralize IL-12 family cytokines, mice were treated i.p. with 200 μg of anti-IL-12p70 (R2–9A5, Bio X Cell), anti-IL-12p40 (C17.8, Bio X Cell) and anti-IL-23p19 (MMp19B2, Biolegend) on d −1, 0 and 2. To block DNAM-1, mice were treated i.p. with 100 μg of anti-DNAM1 (480.1, Biolegend) on d −1 and 0. To induce yellow fluorescent protein (YFP) expression on NKp46+ cells, NKp46-CreERT2^+/− × R26R-EYFP^+/+ mice were treated i.g. with 3.75 mg (males) and 2.5 mg (females) of tamoxifen (Sigma) for five consecutive days, beginning on the day of CPS immunization.

Ivanova D.L., Mundhenke T.M, & Gigley J.P. (2019). THE IL-12– AND IL-23–DEPENDENT NK-CELL RESPONSE IS ESSENTIAL FOR PROTECTIVE IMMUNITY AGAINST SECONDARY TOXOPLASMA GONDII INFECTION. Journal of immunology (Baltimore, Md. : 1950), 203(11), 2944-2958.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!